Assertio Holdings, Inc. announced that its Board of Directors has appointed Brendan P. O?Grady, a highly accomplished pharmaceutical executive, as the Company?s new Chief Executive Officer, effective May 29, 2024. Mr. O?Grady, a senior healthcare executive with more than 30 years of experience accelerating sales growth and profitability, brings to Assertio a demonstrated understanding of multiple commercial models and a track record of market access success. Most recently, Mr. O?Grady was CEO of the Global Formulations business at Glenmark Pharmaceuticals, driving new product launches and focused on growing profitability in key markets.

Prior, he was Chief Commercial and Growth Officer at Amwell, building a go-to-market strategy at the digital telehealth provider. He previously spent 21 years at Teva Pharmaceuticals, rising to CEO of Teva USA and EVP North America Commercial while scaling profitability, growth and productivity. Earlier in his Teva career, he was the Chief Commercial Officer for Global Specialty Medicines as well as Interim Head of Europe Specialty Medicines, Head of North American Generic Medicines, and Head of US Market Access.

Mr. O?Grady holds a Bachelor of Science degree from State University of New York and Master of Business Administration degree from Baker University.